文献速递妇科肿瘤

坚守防线:妇科肿瘤寡进展期全身治疗中的局部控制策略

Hold the line: Local control strategies in oligoprogressive gynecologic cancers during systemic therapy.
PubMed 文献 · Eur J Cancer · 2026-06-19

妇科恶性肿瘤在靶向药物、免疫检查点抑制剂及抗体药物偶联物等治疗进展下,疾病控制与总生存改善,但全身治疗期间进展常见,且多表现为寡复发或寡进展。立体定向放疗、微创手术及影像引导经皮消融等局部区域治疗可安全靶向小体积转移灶,回顾性数据(主要来自PARP抑制剂治疗的卵巢癌队列)提示消融耐药转移克隆可能允许继续有效全身治疗并延长下一线系统治疗无失败生存(NEST-FS)。本综述总结当前证据与未来方向,讨论继续全身治疗同时局部治疗的理由。

要点

  • 妇科肿瘤全身治疗期间寡进展常见,局部区域治疗可靶向小体积转移灶。
  • 回顾性数据提示消融耐药克隆或可延长NEST-FS并维持生活质量。
  • 患者选择、分子特征及治疗顺序是主要挑战,需多学科决策。

核心结论

  • 局部区域治疗联合持续全身治疗在寡进展妇科肿瘤中可能延长下一线系统治疗无失败生存并保持生活质量,但证据有限且异质。

研究设计与样本

  • 本综述总结寡进展妇科肿瘤管理的当前证据与未来方向,讨论继续全身治疗同时局部治疗的理由。

主要发现

  • 回顾性数据主要来自PARP抑制剂治疗的卵巢癌队列,提示消融耐药转移克隆可能允许继续有效全身治疗并延长NEST-FS。
  • 新兴证据支持局部区域治疗与免疫检查点抑制剂及非PARP抑制剂靶向治疗联合的安全性,但数据有限且异质,尤其在子宫内膜癌和宫颈癌中。

临床怎么用

  • 多学科决策至关重要,需综合评估患者选择、疾病与分子特征及治疗顺序。
  • 等待评估持续全身治疗联合局部区域管理策略安全性与有效性的试验结果。

局限性

  • 数据主要来自回顾性卵巢癌队列,证据有限且异质,尤其在子宫内膜癌和宫颈癌中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gynecologic malignancies have undergone significant therapeutic advances with the introduction of targeted agents such as bevacizumab and poly(ADP-ribose) polymerase inhibitors (PARPis), immune checkpoint inhibitors, and, more recently, antibody-drug conjugates. These innovations have improved disease control and overall survival for many patients; however, disease progression during systemic therapy remains common and increasingly presents as oligorecurrent or oligoprogressive disease, characterized by limited metastatic sites in the context of otherwise controlled disease. Concurrent advances in locoregional treatments-including stereotactic body radiotherapy, minimally invasive surgery, and image-guided percutaneous ablation-have expanded the feasibility of safely targeting small-volume metastases. These approaches have demonstrated durable local control in selected patients without concurrent systemic therapy and may offer additional benefit when combined with ongoing treatments. Retrospective data, largely derived from ovarian cancer cohorts treated with PARPis, suggest that ablating resistant metastatic clones may enable continuation of otherwise effective ongoing systemic therapy, prolong next-line systemic treatment-free survival (NEST-FS), and preserve quality of life. Emerging evidence also supports the safety of combining locoregional treatments with immune checkpoint inhibitors and targeted therapies other than PARPis; however, data remain limited and heterogeneous, particularly in endometrial and cervical cancers. Key challenges include patient selection, disease and molecular characterization, treatment sequencing, and survival impact. While multidisciplinary decision-making remains crucial, the results of trials assessing the safety and efficacy of combining ongoing systemic therapies with locoregional management strategies are keenly awaited. Future translational research may improve the detection of oligoprogressive disease and help identify patients most likely to benefit from this strategy. This review summarizes current evidence and future directions in the management of oligoprogressive gynecologic cancers, discussing the rationale for locoregional treatment while continuing systemic therapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Casaccia Giordano F, Lazzari R, Macchia G, et al. Hold the line: Local control strategies in oligoprogressive gynecologic cancers during systemic therapy. Eur J Cancer. 2026. PMID: 42335568. doi:10.1016/j.ejca.2026.116894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。